Physician profile
Don D Luong
NPI 1992904379
$19,825.55
in general payments reported to CMS, 2019-2025
77 companies · $5,293 in 2025
The $5,293 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,707 · 2020: $437 · 2021: $713 · 2022: $1,356 · 2023: $3,536 · 2024: $4,783 · 2025: $5,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $433 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,049.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $433.33 |
| Education | $129.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,572.66 | 2019-2025 | Kisqali, Piqray |
| Celgene Corporation | $1,492.97 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,450.66 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $1,285.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $841.65 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $835.69 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Exelixis INC. | $829.82 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $741.80 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Incyte Corporation | $577.28 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $573.00 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $568.50 | 2019-2025 | |
| Daiichi Sankyo INC. | $565.73 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $563.12 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $518.17 | 2019-2025 | |
| Seagen INC. | $506.32 | 2019-2023 | Tukysa, Padcev, Adcetris |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $474.54 | 2019-2025 | Libtayo |
| Eisai INC. | $408.43 | 2019-2025 | |
| Blueprint Medicines Corporation | $357.09 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $327.42 | 2019-2024 | Tecentriq, Columvi, Polivy |
| Rigel Pharmaceuticals, INC. | $323.21 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $316.33 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Stemline Therapeutics INC. | $314.65 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $313.91 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Amgen INC. | $257.26 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Array Biopharma INC | $251.77 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $225.29 | 2019-2025 | Padcev, Xtandi, Xospata |
| Kite Pharma, INC. | $168.32 | 2020-2025 | Yescarta |
| Pharmaessentia USA Corporation | $157.10 | 2022-2025 | Besremi |
| Karyopharm Therapeutics INC. | $148.28 | 2020-2023 | Xpovio |
| Beigene USA, INC. | $146.44 | 2023-2024 | Brukinsa, Tevimbra |
| Adaptive Biotechnologies Corporation | $137.52 | 2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $129.30 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $122.73 | 2019-2025 | Onivyde, Somatuline Depot |
| Sobi, INC | $119.38 | 2024-2025 | |
| Tersera Therapeutics LLC | $118.05 | 2023-2025 | Zoladex |
| Taiho Oncology, INC. | $117.34 | 2024-2025 | |
| Csl Behring | $116.53 | 2022-2025 | Idelvion, Afstyla |
| Janssen Pharmaceuticals, INC | $110.67 | 2019-2023 | Xarelto |
| Aveo Pharmaceuticals, INC. | $109.12 | 2022-2025 | Fotivda |
| Tesaro, INC. | $106.96 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $99.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $94.80 | 2023-2025 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $94.20 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $93.02 | 2023-2025 | Monoferric, Cosela |
| Emd Serono, INC. | $92.41 | 2019-2025 | |
| Intuitive Surgical, INC. | $86.61 | 2019 | |
| Kyowa Kirin, INC. | $85.00 | 2024-2025 | Poteligeo |
| Puma Biotechnology, INC. | $70.91 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $67.01 | 2022-2023 | Qinlock |
| Jazz Pharmaceuticals INC. | $56.53 | 2023-2025 | Zepzelca |
| Myriad Genetic Laboratories, INC. | $56.03 | 2022-2025 | Myrisk |
| Sumitomo Pharma America, INC. | $54.27 | 2023-2025 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $47.55 | 2024-2025 | Empaveli |
| Genmab U.S., INC. | $45.95 | 2023-2024 | Epkinly |
| Mirati Therapeutics, INC. | $38.69 | 2024 | Krazati |
| Legend Biotech USA INC. | $35.49 | 2025 | Carvykti |
| Novocure INC. | $28.30 | 2024 | Optune |
| Shire North American Group INC | $26.30 | 2019 | |
| Geron Corporation | $25.68 | 2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $24.90 | 2025 | |
| Fennec Pharmaceuticals, INC. | $23.76 | 2024 | Pedmark |
| Delcath Systems | $23.59 | 2025 | Hepzato Kit |
| G1 Therapeutics, INC. | $22.89 | 2023 | Cosela |
| Tempus Ai, INC | $22.73 | 2024 | Xt Cdx |
| Springworks Therapeutics, INC. | $22.55 | 2024 | Ogsiveo |
| Iovance Biotherapeutics, INC. | $21.44 | 2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $18.97 | 2023 | Givlaari |
| Heron Therapeutics, INC. | $17.88 | 2019 | |
| Morphosys, US INC. | $17.32 | 2024 | Monjuvi |
| Cti Biopharma Corp. | $17.28 | 2023 | Vonjo |
| Myovant Sciences INC. | $16.18 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.23 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.07 | 2022 | |
| Spectrum Pharmaceuticals INC. | $12.51 | 2019 | |
| Agios Pharmaceuticals, INC. | $11.35 | 2019 | |
| Pharmaand Gmbh | $10.35 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Luong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.